January 20, 2026 08:50 AM EST
Fastenal Stock Drops After Q4 Sales, Operating Income Margin Slightly Miss Estimates
FROM 3 minutes ago
Shares of Fastenal (FAST) sank 6.5% in premarket trading after the industrial distributor reported fiscal 2025 fourth-quarter net sales and operating income margin that narrowly missed analysts’ estimates.
The Winona, Minn.-based firm, which bills itself as “a leader in the wholesale distribution of industrial and construction supplies,” posted net sales that rose 11% year-over-year to just below $2.03 billion and operating margin of 19.0%. Analysts surveyed by Visible Alpha had expected just above $2.03 billion and 19.4%, respectively.
Fastenal’s profit of $0.26 per share matched consensus expectations.
The company said that “broader market conditions remain mixed, with ongoing challenges in industrial production.”
Fastenal shares entered Tuesday having risen about 15% over the past year.
TradingView
January 20, 2026 08:06 AM EST
Trump Is Set to Unveil Big Plans Addressing Housing Affordability This Week. Here’s What We Know
FROM 47 minutes ago
Housing affordability has been a problem for the U.S. economy in recent years, and President Donald Trump is set to roll out what he describes as a series of “aggressive” reforms for the housing market this week.
Trump has said he will use his Wednesday speech at the World Economic Forum annual meeting in Davos, Switzerland, to lay out his ideas for the housing market. Trump and his advisors have signaled that the plans could have big implications for mortgages and how Americans buy homes.
Fabrice Coffrini / AFP via Getty Images
Here’s what we know about the plan so far.
Read the full article here.
January 20, 2026 07:46 AM EST
RAPT Therapeutics Stock Skyrockets as GSK Buys Biopharmaceutical Firm for $2.2B
FROM 1 hr 7 min ago
Tuesday is looking like it’ll be a rough day for stocks. That does not appear to be the case for RAPT Therapeutics (RAPT) shareholders.
RAPT Therapeutics shares added nearly two-thirds of their value in premarket trading after drug giant GSK (GSK) said it had agreed to purchase the California-based biopharmaceutical firm for roughly $2.2 billion in stock.
GSK will pay RAPT Therapeutics shareholders $58.00 per share at closing—a 65% premium to Friday’s closing price of $35.10—and said its upfront investment is about $1.9 billion.
The deal, which is expected to close in the first quarter of 2026, would give GSK global rights to experimental food-allergy drug ozureprubart, excluding mainland China, Macau, Taiwan and Hong Kong.
“Food allergies cause severe health impacts to patients with existing treatment requiring injections as frequently as every 2 weeks,” GSK Chief Scientific Officer Tony Wood said. “Ozureprubart offers the opportunity to bring sustained protection to patients with dosing every 12 weeks, and is consistent with our approach to acquire assets that address validated targets and where there is clear unmet medical need.”
RAPT Therapeutics shares entered Tuesday up roughly 265% over the past year.
TradingView
January 20, 2026 07:00 AM EST
Stock Futures Dive After Trump Threatens New Tariffs Over Greenland
FROM 1 hr 53 min ago
Futures contracts connected to the Dow Jones Industrial Average pointed down 1.3%.
TradingView
S&P 500 futures pointed down 1.6%.
TradingView
Nasdaq 100 futures sank 1.9%.
TradingView